Clinical Trials on Purpura, Thrombocytopenic in United States

Total 367 results

GlaxoSmithKline

Completed

Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect

Purpura, Thrombocytopaenic, Idiopathic

United States
Amgen

Completed

Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

Thrombocytopenia | Immune Thrombocytopenia | Idiopathic Thrombocytopenic Purpura | Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenic Purpura

United States, Canada, Australia
GlaxoSmithKline

Completed

Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP) (PETIT)

Purpura, Thrombocytopaenic, Idiopathic

United States, France, Netherlands, Spain, United Kingdom, Canada
Eisai Inc.

Completed

A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects

Idiopathic Thrombocytopenia Purpura

United States
GlaxoSmithKline

Completed

RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag (RAISE)

Purpura, Thrombocytopaenic, Idiopathic

United States, Taiwan, Italy, Poland, Peru, Canada, Denmark, Germany, Slovakia, Spain, United Kingdom, New Zealand, China, Greece, Hong Kong, Russian Federation, Austria, Netherlands, Czech Republic, France, India, Ukraine, Tunisia, F... and more
GlaxoSmithKline

Completed

Study In Healthy Subjects To Evaluate The Photo-Irritant Potential Of Eltrombopag

Purpura, Thrombocytopaenic, Idiopathic

United Kingdom
Weill Medical College of Cornell University
Genentech, Inc.

Withdrawn

Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura

Thrombotic Thrombocytopenic Purpura

United States
Weill Medical College of Cornell University

Terminated

A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone (Dex/Rituxan)

Idiopathic Thrombocytopenia Purpura

United States
Octapharma

Terminated

Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP)

Thrombotic Thrombocytopenic Purpura (TTP)

United States
Hematology and Oncology Specialists

Unknown

Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura

Autoimmune Thrombocytopenic Purpura

United States
Bloodworks
University of Washington

Completed

A Pilot Study of N-acetylcysteine in Thrombotic Thrombocytopenia Purpura (NACinTTP)

Purpura, Thrombotic Thrombocytopenic | TTP

United States
GlaxoSmithKline

Completed

LENS - Long-term Eltrombopag Observational Study (LENS)

Purpura, Thrombocytopaenic, Idiopathic

United States, Bulgaria, Italy, Peru, Russian Federation, Canada, France, Germany, Hong Kong, Spain, Sweden, United Kingdom, Hungary, Poland, Ukraine, Czech Republic, India, Australia, Tunisia, Puerto Rico, Pakistan
Ohio State University
Food and Drug Administration (FDA)

Completed

Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)

Thrombotic Thrombocytopenic Purpura

United States
Weill Medical College of Cornell University
Genentech, Inc.

Withdrawn

A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone

Idiopathic Thrombocytopenic Purpura (ITP)

United States
Eisai Inc.

Terminated

A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

Idiopathic Thrombocytopenic Purpura

United States
Neufeld, Ellis J, MD, PhD
Terrana ITP Research Fund

Completed

Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura

Idiopathic Thrombocytopenic Purpura | Immune Thrombocytopenic Purpura

United States
Icahn School of Medicine at Mount Sinai
Beth Israel Medical Center

Terminated

Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP) (TTP)

Thrombotic Thrombocytopenic Purpura

United States
Eisai Inc.

Completed

Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine.

Idiopathic Thrombocytopenic Purpura (ITP)

United States
Baxalta now part of Shire

Completed

Prospective Psychometric Evaluation Study of a Patient-reported Outcomes (PRO) Instrument for Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP]

Congenital Thrombotic Thrombocytopenic Purpura

United States, United Kingdom
GlaxoSmithKline

Completed

Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment

Purpura, Thrombocytopaenic, Idiopathic

United States, Australia, New Zealand
Octapharma

Terminated

Octaplas Adult TTP Trial

Thrombotic Thrombocytopenic Purpura

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura

Nonneoplastic Condition

United States
Principia Biopharma, a Sanofi Company

Active, not recruiting

A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia | Immune Thrombocytopenic Purpura

United States, Australia, Bulgaria, Canada, Czechia, Netherlands, Norway, United Kingdom
Amgen

Completed

Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim

Idiopathic Thrombocytopenic Purpura

Italy, United States, Germany, Czechia, United Kingdom, Australia, Spain, Poland, France
Sanofi

Completed

Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)

Acquired Thrombotic Thrombocytopenic Purpura

United States, Austria, Belgium, Canada, Czechia, France, Hungary, Israel, Italy, Spain, Switzerland, Turkey, United Kingdom
GlaxoSmithKline

Completed

A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Purpura, Thrombocytopaenic, Idiopathic

Italy, Germany, Hong Kong, Korea, Republic of, United States, Pakistan, Russian Federation, India, Czech Republic, Hungary, France
Genentech, Inc.

Completed

A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic Purpura

HIV Infections | Immune Thrombocytopenic Purpura ( ITP )

United States
Amgen

Completed

A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura

Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP

United States, Canada, Australia, Spain
Shire
Takeda Development Center Americas, Inc.

Completed

Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) (SOAR-HI)

Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

United States, Spain, Canada, United Kingdom, France, Germany, Italy
Ablynx, a Sanofi company

Completed

Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) (TITAN)

Acquired Thrombotic Thrombocytopenic Purpura

United States, Austria, Belgium, France, Germany, Israel, Italy, Spain, Switzerland, United Kingdom, Bulgaria, Romania, Australia
Veralox Therapeutics

Recruiting

A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia

Heparin Induced Thrombocytopenia | Thrombocytopenia, Immune

United States
Weill Medical College of Cornell University
Genentech, Inc.; Biogen

Completed

Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP

Immune Thrombocytopenic Purpura

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between Platelet Counts, Endogenous Thrombopoietin Levels, Endogenous Anti-Thrombopoietin Antibodies, and Selected Autoimmune Markers

Purpura, Thrombocytopenic, Idiopathic | Immune Thrombocytopenic Purpura

United States
Novartis Pharmaceuticals

Completed

EXTEND (Eltrombopag Extended Dosing Study) (EXTEND)

Purpura, Thrombocytopaenic, Idiopathic

United Kingdom, Hong Kong, United States, Germany, Italy, Netherlands, Spain, Taiwan, Thailand, Canada, Denmark, Pakistan, Romania, Slovenia, Russian Federation, Slovakia, Sweden, Poland, China, New Zealand, Ukraine, Australia, Austria and more
University College, London

Recruiting

The United Kingdom Thrombotic Thrombocytopenic Purpura Registry (UK TTP Registry)

TTP - Thrombotic Thrombocytopenic Purpura

United Kingdom
University College, London

Completed

The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP)

Thrombotic Thrombocytopenic Purpura (TTP)

United Kingdom
Baxalta now part of Shire

Completed

Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)

Hereditary Thrombotic Thrombocytopenic Purpura (TTP)

United States, Germany, United Kingdom, Switzerland, Austria, Japan, Poland
Washington University School of Medicine
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura

Thrombotic Thrombocytopenic Purpura

United States
Insel Gruppe AG, University Hospital Bern
Swiss National Science Foundation; Mach Gaensslen Foundation; Baxalta Innovations...

Recruiting

Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome) (TTP registry)

Thrombotic Thrombocytopenic Purpura | Congenital Thrombotic Thrombocytopenic Purpura | Familial Thrombotic Thrombocytopenic Purpura | Thrombotic Thrombocytopenic Purpura, Congenital | Upshaw-Schulman Syndrome

United States, Austria, Czechia, Germany, Japan, Norway, Switzerland
GlaxoSmithKline

Completed

SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP)

Purpura, Thrombocytopaenic, Idiopathic

Thailand, Korea, Republic of, United Kingdom, New Zealand, Germany, Greece, Hong Kong, Pakistan, Poland, Romania, Russian Federation, Slovenia, Taiwan
GlaxoSmithKline

Completed

Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment

Purpura, Thrombocytopaenic, Idiopathic

United States
Genzyme, a Sanofi Company

Terminated

Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

Idiopathic Thrombocytopenic Purpura

United States
New York Medical College

Recruiting

Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura (NYMC207)

Immune Thrombocytopenic Purpura

United States
Neufeld, Ellis J, MD, PhD
Genentech, Inc.; Biogen; Glaser Pediatric Research Network; Terrana ITP Research...

Completed

Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Immune Thrombocytopenic Purpura (ITP) | Idiopathic Thrombocytopenic Purpura (ITP)

United States
Gilead Sciences

Terminated

Study of Veltuzumab (hA20) at Different Doses in Patients With ITP

Purpura, Thrombocytopenic, Idiopathic | Autoimmune Thrombocytopenic Purpura | Purpura, Thrombocytopenic, Autoimmune

United States
Takeda
Shire; Takeda Development Center Americas, Inc.

Recruiting

A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

Thrombotic Thrombocytopenic Purpura (TTP)

China, United States, France, Japan, Poland, Germany, Austria, Spain, Italy, Switzerland, United Kingdom
Takeda
Takeda Development Center Americas, Inc.

Recruiting

A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

Thrombotic Thrombocytopenic Purpura (TTP)

United States, Spain, Italy, Greece, United Kingdom, Argentina, Poland, Austria
Novartis Pharmaceuticals

Completed

A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP (TAPER)

Immune Thrombocytopenic Purpura (ITP)

Spain, Italy, Greece, Switzerland, United Kingdom, France, Turkey, Russian Federation, Brazil, Austria, Mexico, Oman, Chile, Japan, United States
Weill Medical College of Cornell University
Children's Hospital of Orange County

Completed

A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013

Immune Thrombocytopenia

United States
Liverpool University Hospitals NHS Foundation Trust

Recruiting

The ConNeCT Study: Neurological Complications of TTP

Thrombotic Thrombocytopenic Purpura

United Kingdom

Clinical Trials on Purpura, Thrombocytopenic in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations